Discussion Points for Recommendations Draft

1
Discussion Points for Recommendations Draft

• Thought/comments on the Draft Recommendations
  Draft
• Development of Models and Use of Data
• Draft Document
• Are we missing something in the recommendations?
• Are there issues that need clarification?
• Are the recommendations useful?
• Are there better (or other) examples?
• Additional/better references?
• Revising the document?
• When and where to send comments?

2
Discussion Points for Recommendations

• Context of Development/Use
• What are the challenges to developing methods?
• How to balance resources for phenotype vs
  toxpathway approaches?
• eg. Pathway apoptosis?
• eg. Migration phenotype?
• Phenotypic we can do now
• How many ToxPathways do we know for
  neurodevelopmental toxicants?
• Can phenotypic assays be used more for screening
  for prioritization
• Phenotypic assays are aggregative of many targets
  
• What is a hit? Biology vs statistics.
• What are the appropriate anchors? If not
  cytototoxicty, then what?
• Are there approaches that will enhance the use in
  risk assessment?
• In vitro kinetics tie in to human environmental
  levels
• Screening for predictive toxicity vs screening
  for prioritization impact on approaches?